Dyax Corp. (NASDAQ:DYAX) shares are up 47% today after the company announced positive data from the Phase 1b clinical study of its investigational product, DX-2930, which is being developed …
Dyax Corp. (NASDAQ:DYAX) saw a gain of over 40% in pre-market trading Wednesday with the release of phase 1b results for DX-2930, an …
Oppenheimer analyst Akiva Felt reiterated an Outperform rating on Dyax Corp (NASDAQ:DYAX) and slightly raised his price target to $14 (from $13). Felt noted, …
